Back to Journals » OncoTargets and Therapy » Volume 11
Original Research
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Low-dose hypomethylating agent decitabine in combination with aclacinomycin and cytarabine achieves a better outcome than standard FLAG chemotherapy in refractory/relapsed acute myeloid leukemia patients with poor-risk cytogenetics and mutations
Total article views | HTML views | PDF downloads | Totals | ||
---|---|---|---|---|---|
9,026 | Dovepress* | 8,395+ | 829 | 9,224 | |
PubMed Central* | 631 | 188 | 819 | ||
Totals | 9,026 | 1,017 | 10,043 | ||
*Since 12 October 2018 |
View citations on PubMed Central and Google Scholar